Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02077894 · ClinicalTrials.gov registry record

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

A clinical trial of Genetic Eye Disease, sponsored by National Eye Institute (NEI).

Recruiting
Registry status
2,000
Enrollment target
1
Study location

NCT02077894: Recruiting study of Genetic Eye Disease, sponsored by National Eye Institute (NEI).

NCT02077894 is a study of Genetic Eye Disease that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02077894, a study of Genetic Eye Disease, is actively recruiting participants, sponsored by National Eye Institute (NEI).

RECRUITING
Registry status
2,000 participants
Enrollment target
1
Study location

Study Summary

Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing (referred to as exome sequencing and genome sequencing in the remainder of the document). This includes identifying mutations in known genes or novel genes for recognized conditions, as well as identifying mutations in novel genes for previously uncharacterized genetic conditions involving the eye. Study Population: We plan to recruit 2,000 participants, to include both participants with an eye condition under study and unaffected family members. Ideally unaffected family members will be parents of an affected participant. Design: Participants will be self-referred or referred by an outside clinician. They will preferably be evaluated at the National Institutes of Health (NIH), but the option to participate offsite will be offered. Participants evaluated onsite will be recruited through other pre-existing NIH protocols, such as the National Eye Institute (NEI) Screening protocol (08-EI-0102), the NEI Ocular Natural History protocol (16-EI-0134), the Genetics of Inherited Eye Disease protocol (15-EI-0128), and the Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC) protocol (13-EI-0049). Offsite participants will be screened via phone or secure videoconference, and records will be requested for evaluation of affected participants. Both affected and unaffected eligible participants will undergo genetic counseling and will provide a blood sample and/or saliva sample for exome or genome sequencing. Biological relationships will be confirmed prior to exome or genome sequencing. Sequence data will be analyzed for primary variants and secondary findings, unless participants choose to opt-out of secondary analysis and reporting. All sequence variants deemed clinically relevant will be validated in a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory and the results will be returne

Primary Outcome

This is an etiologic study that will generate molecular information about previously-recognized conditions for which participants did not have a molecular diagnosis, as well as molecular information for previously uncharacterized eye conditions.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, - Bethesda

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2014-08-05
Est. Completion 2029-08-05
National Eye Institute (NEI)

221 total trials

What NCT02077894 shows while recruiting

NCT02077894 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 1 condition, with Genetic Eye Disease appearing as the primary indexed condition, and to 0 interventions.

NCT02077894 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02077894 about?

NCT02077894 is a clinical study titled "Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions". Objective: The objective of this study is to identify genetic causes of inherited eye conditions through whole exome or whole genome sequencing (referred to as exome sequencing and genome sequencing in the remainder of the document). This includes identifying mutations in known genes or novel genes ...

What is the current status of trial NCT02077894?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2014-08-05. Estimated completion is 2029-08-05.

What conditions does trial NCT02077894 study?

This clinical trial studies the following conditions: Genetic Eye Disease.

Who is sponsoring clinical trial NCT02077894?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02077894 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Genetic Eye Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02077894, the US trial registry maintained by the National Library of Medicine. NCT02077894 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.